DE60112433D1 - Wasserlösliche wirkstoffvorstufen von azolverbindungen - Google Patents

Wasserlösliche wirkstoffvorstufen von azolverbindungen

Info

Publication number
DE60112433D1
DE60112433D1 DE60112433T DE60112433T DE60112433D1 DE 60112433 D1 DE60112433 D1 DE 60112433D1 DE 60112433 T DE60112433 T DE 60112433T DE 60112433 T DE60112433 T DE 60112433T DE 60112433 D1 DE60112433 D1 DE 60112433D1
Authority
DE
Germany
Prior art keywords
water
active ingredients
soluble active
compounds
azol compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112433T
Other languages
English (en)
Other versions
DE60112433T2 (de
Inventor
Yasutsugu Ueda
D Matiskella
Jerzy Golik
W Hudyma
Chung-Pin Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE60112433D1 publication Critical patent/DE60112433D1/de
Application granted granted Critical
Publication of DE60112433T2 publication Critical patent/DE60112433T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polymerization Catalysts (AREA)
DE60112433T 2000-01-20 2001-01-16 Wasserlösliche wirkstoffvorstufen von azolverbindungen Expired - Lifetime DE60112433T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17716900P 2000-01-20 2000-01-20
US177169P 2000-01-20
US24996900P 2000-11-20 2000-11-20
US249969P 2000-11-20
PCT/US2001/001284 WO2001052852A1 (en) 2000-01-20 2001-01-16 Water soluble prodrugs of azole compounds

Publications (2)

Publication Number Publication Date
DE60112433D1 true DE60112433D1 (de) 2005-09-08
DE60112433T2 DE60112433T2 (de) 2006-05-18

Family

ID=26873001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112433T Expired - Lifetime DE60112433T2 (de) 2000-01-20 2001-01-16 Wasserlösliche wirkstoffvorstufen von azolverbindungen

Country Status (22)

Country Link
US (1) US6362172B2 (de)
EP (1) EP1284737B1 (de)
JP (1) JP3766804B2 (de)
KR (1) KR100748299B1 (de)
CN (1) CN1178665C (de)
AT (1) ATE300946T1 (de)
AU (1) AU782177C (de)
BR (1) BR0107618A (de)
CA (1) CA2397734C (de)
CZ (1) CZ20022822A3 (de)
DE (1) DE60112433T2 (de)
DK (1) DK1284737T5 (de)
ES (1) ES2247131T3 (de)
HU (1) HU229226B1 (de)
IL (2) IL150798A0 (de)
MX (1) MXPA02007120A (de)
NO (1) NO330352B1 (de)
NZ (1) NZ519354A (de)
PL (1) PL206024B1 (de)
PT (1) PT1284737E (de)
RU (1) RU2266909C2 (de)
WO (1) WO2001052852A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP2161275A1 (de) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs aus 2,4-Pyrimidindiamin-Verbindungen und ihre Verwendungen
JO2691B1 (en) 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2632842C (en) * 2005-12-20 2013-06-25 Eisai R & D Management Co., Ltd. Process for preparation of water-soluble azole prodrugs
WO2007092580A2 (en) * 2006-02-08 2007-08-16 Phibro-Tech Inc. Biocidal azole emulsion concentrates having high active ingredient content
CN101389333A (zh) 2006-02-22 2009-03-18 卫材R&D管理有限公司 稳定化药物组合物
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2291348A4 (de) 2008-05-20 2013-05-15 Neurogesx Inc Wasserlösliche acetaminophenanaloga
AU2009249069A1 (en) * 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US20130288956A1 (en) 2010-11-05 2013-10-31 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
RU2618456C2 (ru) * 2010-12-16 2017-05-03 Плэтформ Брайтворкс Ту, Лтд Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
EP3517539B1 (de) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
IN2014DN06792A (de) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2616442T3 (es) 2012-04-20 2017-06-13 Eisai R&D Management Co., Ltd. Formulación encapsulada
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EA201592236A1 (ru) 2013-06-04 2016-06-30 Вайом Байосайнсиз Пвт. Лтд. Частицы с нанесенным покрытием и композиции, включающие такие частицы
MX2016009898A (es) 2014-01-29 2017-01-23 Vyome Biosciences Pvt Ltd Tratamientos para acne resistente.
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN104926870B (zh) * 2014-03-21 2017-02-08 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法
WO2017019875A1 (en) * 2015-07-28 2017-02-02 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compounds prodrugs and their uses
EP3468562A1 (de) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin
CN107501255B (zh) * 2017-09-12 2019-08-23 成都施贝康生物医药科技有限公司 一种艾沙康唑衍生物及其用途
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111527C (en) 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives
CA2129288C (en) 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
CZ294823B6 (cs) 1993-12-21 2005-03-16 Schering Corporation Fungicidní tetrahydrofurany
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
SI0741737T1 (en) 1994-01-24 2000-02-29 Janssen Pharmaceutica N.V. Watersoluble azole antifungals
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
AR002751A1 (es) 1995-06-02 1998-04-29 Schering Corp Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
EP0829478A3 (de) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium und N-Benzyltriazolium Derivate, deren Herstellung und deren Verwendung als fungizides und anti-mykotisches Mittel
ATE252590T1 (de) 1998-01-29 2003-11-15 Bristol Myers Squibb Co Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
US5883097A (en) 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
WO2000030655A1 (en) * 1998-11-20 2000-06-02 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Also Published As

Publication number Publication date
KR100748299B1 (ko) 2007-08-09
AU782177B2 (en) 2005-07-07
CA2397734A1 (en) 2001-07-26
US20010041691A1 (en) 2001-11-15
PL206024B1 (pl) 2010-06-30
US6362172B2 (en) 2002-03-26
PT1284737E (pt) 2005-11-30
JP3766804B2 (ja) 2006-04-19
KR20020070492A (ko) 2002-09-09
NO330352B1 (no) 2011-04-04
CZ20022822A3 (cs) 2003-02-12
WO2001052852A1 (en) 2001-07-26
HUP0204405A3 (en) 2005-02-28
BR0107618A (pt) 2002-11-12
IL150798A (en) 2006-08-01
MXPA02007120A (es) 2003-01-28
IL150798A0 (en) 2003-02-12
CN1395485A (zh) 2003-02-05
CA2397734C (en) 2010-08-17
HUP0204405A2 (en) 2003-05-28
EP1284737A4 (de) 2003-03-19
HU229226B1 (en) 2013-09-30
ATE300946T1 (de) 2005-08-15
RU2266909C2 (ru) 2005-12-27
CN1178665C (zh) 2004-12-08
DE60112433T2 (de) 2006-05-18
NZ519354A (en) 2004-05-28
EP1284737A1 (de) 2003-02-26
NO20023468L (no) 2002-07-29
ES2247131T3 (es) 2006-03-01
JP2003520235A (ja) 2003-07-02
EP1284737B1 (de) 2005-08-03
PL356164A1 (en) 2004-06-14
DK1284737T3 (da) 2005-11-28
AU2948501A (en) 2001-07-31
NO20023468D0 (no) 2002-07-19
DK1284737T5 (da) 2007-09-24
AU782177C (en) 2007-10-18

Similar Documents

Publication Publication Date Title
DE60112433D1 (de) Wasserlösliche wirkstoffvorstufen von azolverbindungen
ATE289750T1 (de) Fungizide wirkstoffkombinationen
WO2001051456A3 (en) Antibacterial agents
AU2864002A (en) Compounds having fungicidal activity and processes to make and use same
DE60027606D1 (de) Polyphenolisches protein enthaltende bioadhäsive zusammensetzung
DE60012188D1 (de) Fungizide
MXPA02006826A (es) Un inhibidor de division celular y un metodo de produccion del mismo.
SE0004245D0 (sv) Novel compounds and their use
AU5970199A (en) Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity
NO20032241D0 (no) Forbedret prosess for vannlöselige azolforbindelser
MXPA02011039A (es) Combinaciones de productos activos fungicidas.
WO2001009122A3 (en) Serotonergic benzofurans
TR199901017A2 (xx) B�cek ilac� terkibi.
SI1244643T1 (en) Tryptase inhibitors
ATE250338T1 (de) Antiseptische zusammensetzungen
WO2001046128A3 (en) Tryptase inhibitors
ES2188899T3 (es) Agente antifungico.
UY26541A1 (es) Profármacos de compuestos de azol solubles en agua.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKYO, JP